Actively Recruiting
Investigation of Cardiac Amyloid Deposits as a Cause of Cardiac Dysfunction in Alzheimer's Disease
Led by University Hospital, Essen · Updated on 2025-09-04
15
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the possible shared causes of cardiac amyloidosis and Alzheimer's disease, both involving amyloid deposits. This observational study uses Positron Emission Tomography (PET) scans with amyloid tracers, typically used for Alzheimer's imaging, to also examine amyloid deposits in the heart. The goal is to improve diagnosis methods for both conditions by exploring their connection. Participants are patients clinically referred for cerebral amyloid PET scans to clarify an Alzheimer's diagnosis. In addition to the brain PET scan, the study adds cardiac PET/MRI imaging without extra substances or radiation. Participants also receive a transthoracic echocardiogram with strain analysis and a 12-lead electrocardiogram (EKG) as part of a comprehensive diagnostic assessment. During the study, each participant undergoes clinical dementia evaluation along with the imaging tests. Researchers observe the frequency of cardiac amyloid deposits overall and in relation to disease stages over about one year. The study includes regular heart and brain assessments to monitor amyloid presence and heart function, aiming to better understand their link in Alzheimer’s disease.
CONDITIONS
Brief Title
Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients undergoing cerebral amyloid PET examination for clinical indication to clarify Alzheimer's disease
- No contraindications to undergo an MRI examination
- No contraindications to undergo an Amyloid PET scan
- Age 18 years or older
You will not qualify if you...
- Patients with vascular dementia and confirmed other causes of dementia such as stroke, vitamin deficiency, thyroid insufficiency, or toxic causes like alcohol
- Patients with pronounced cardiac preconditions
- Pregnant and breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 day
Participants undergo a comprehensive diagnostic evaluation including cerebral amyloid PET, cardiac PET/MRI imaging, transthoracic echocardiogram with strain analysis, and a 12-lead electrocardiogram (EKG).
1 visit (in-person)
Duration - Approximately 1 year
Participants are observed over an average of 1 year to evaluate the frequency of cardiac amyloid deposits and their relation to Alzheimer's disease manifestations.
Trial Site Locations
Total: 1 location
1
University Hospital Essen
Essen, North Rhine-Westphalia, Germany, 45147
Actively Recruiting
Research Team
D
David Kersting, MD PhD
S
Stephan Settelmeier, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here